Literature DB >> 17079947

The association of acetyl-l-carnitine and nicotinamide remits the experimental diabetes in mice by multiple low-dose streptozotocin.

Juan C Cresto1, Lidia E Fabiano de Bruno, Gabriel F Cao, Claudia F Pastorale, Nicolas Confalonieri, María del Carmen Camberos, Juan C Basabe.   

Abstract

OBJECTIVES: We studied the effect of acetyl-l-carnitine plus nicotinamide (AC + N) on murine diabetes mellitus induced by multiple low doses of streptozotocin.
METHODS: Male C57BL/6J inbred mice were injected intraperitoneally with citrate buffer or streptozotocin (40 mg/kg) for 5 consecutive days, followed by injections of saline solution or AC + N (50 + 25 mg/kg) from days 6 to 110. Four groups were studied: normal control mice (C), treated normal control mice (TC), diabetic mice (D), and treated diabetic mice (TD). TD group was divided into 2 at day 86; treatment was suspended in one group (TDs) and continued in the other until day 110.
RESULTS: Weight, plasma glucose, plasma insulin, cellular immune aggression, glucose-stimulated insulin secretion from perifused pancreatic slices, and pancreas histology were studied in each experimental group. Diabetic mice treated with AC + N showed improvements in weight, plasma glucose, and plasma insulin levels without mortality, reaching control values at day 110. Cellular immune aggression and insulin release from pancreatic slices perfusions improved without reaching control values. Histology showed that insulin-immunostained area, the index of insulin immunostained beta cells and beta-cell size, was normalized at the end of the study.
CONCLUSIONS: The treatment with AC + N induced remission of autoimmune type 1 diabetes in mice produced by multiple low doses of streptozotocin.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079947     DOI: 10.1097/01.mpa.0000236740.07854.b1

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  8 in total

1.  Enhanced tolerance against early and late apoptotic oxidative stress in mammalian neurons through nicotinamidase and sirtuin mediated pathways.

Authors:  Zhao Zhong Chong; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2008-08       Impact factor: 1.990

Review 2.  Novel avenues of drug discovery and biomarkers for diabetes mellitus.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Jinling Hou
Journal:  J Clin Pharmacol       Date:  2010-03-10       Impact factor: 3.126

3.  Diabetes mellitus: channeling care through cellular discovery.

Authors:  Kenneth Maiese; Yan Chen Shang; Zhao Zhong Chong; Jinling Hou
Journal:  Curr Neurovasc Res       Date:  2010-02       Impact factor: 1.990

Review 4.  Novel directions for diabetes mellitus drug discovery.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Shaohui Wang
Journal:  Expert Opin Drug Discov       Date:  2012-10-24       Impact factor: 6.098

Review 5.  Triple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  Biomed Pharmacother       Date:  2008-02-20       Impact factor: 6.529

6.  Exposure to inorganic arsenic and its methylated metabolites alters metabolomics profiles in INS-1 832/13 insulinoma cells and isolated pancreatic islets.

Authors:  Yuan-Yuan Li; Christelle Douillet; Madelyn Huang; Rowan Beck; Susan Jenkins Sumner; Miroslav Styblo
Journal:  Arch Toxicol       Date:  2020-04-10       Impact factor: 6.168

Review 7.  The vitamin nicotinamide: translating nutrition into clinical care.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Jinling Hou; Yan Chen Shang
Journal:  Molecules       Date:  2009-09-09       Impact factor: 4.411

8.  Children who develop type 1 diabetes early in life show low levels of carnitine and amino acids at birth: does this finding shed light on the etiopathogenesis of the disease?

Authors:  G la Marca; S Malvagia; S Toni; B Piccini; V Di Ciommo; G F Bottazzo
Journal:  Nutr Diabetes       Date:  2013-10-28       Impact factor: 5.097

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.